54,177 Shares in Haleon plc (NYSE:HLN) Bought by First Trust Advisors LP

First Trust Advisors LP bought a new stake in shares of Haleon plc (NYSE:HLN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 54,177 shares of the company's stock, valued at approximately $517,000.

Several other large investors have also bought and sold shares of the company. FMR LLC boosted its position in Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after acquiring an additional 3,909,545 shares during the period. Wellington Management Group LLP lifted its holdings in Haleon by 67.5% in the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after purchasing an additional 6,175,835 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Haleon by 0.8% during the fourth quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company's stock worth $72,793,000 after buying an additional 58,444 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Haleon by 18.3% during the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company's stock worth $57,382,000 after buying an additional 930,701 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Haleon during the fourth quarter worth approximately $42,193,000. Institutional investors own 6.67% of the company's stock.

Analyst Upgrades and Downgrades

HLN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. HSBC reissued a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective for the company in a research report on Friday, May 9th. Finally, Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.25.

Haleon Price Performance

HLN stock traded up $0.25 during midday trading on Thursday, reaching $10.65. 13,758,061 shares of the stock were exchanged, compared to its average volume of 7,964,789. The stock has a market capitalization of $48.01 billion, a PE ratio of 31.28, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a 52 week low of $8.25 and a 52 week high of $10.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a fifty day moving average price of $10.21 and a 200 day moving average price of $9.85.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon's dividend payout ratio is 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.